Orexigen Therapeutics, Inc. at Piper Jaffray Healthcare Conference (Replay)
12/03/13 at 11:00 a.m. ET
Orexigen Therapeutics, Inc. Contrave Light Study Interim Analysis Conference Call and Webcast (Replay)
11/25/13 at 8:30 a.m. ET
Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead product candidate is Contrave®, which has completed Phase III clinical trials and for which a New Drug Application has been submitted and reviewed by the FDA. The Company has also reached agreement with the FDA on a Special Protocol Assessment (SPA) for the Light Study, the Contrave cardiovascular outcomes trialMore >>
Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.